Infinity's horizons broaden with rich AbbVie co-development deal
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals will expand its capacity for single-agent and combination therapy oncology studies for duvelisib (IPI-145), and improve its ability to pay future milestone and royalty fees under prior agreements, through an $805m partnership with AbbVie.
You may also be interested in...
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.